Zenivol (tetrahydrocannabinol/cannabidiol) / Zelira - LARVOL DELTA

Zelira Therapeutics (ASX:ZLD) expands into Germany with distribution agreement (The Market Herald) - "Zelira Therapeutics (ZLD) has expanded into Germany via a five-year distribution agreement. The agreement with IM Cannabis Corp, a subsidiary of Adjupharm, will see Zelira’s cannabinoid-based insomnia medication, Zenivol, be distributed into the German market. The agreement took effect on 17 September and allows Zelira to supply finished dosages of Zenivol from Australia to Germany. To retain exclusivity, Adjupharm must purchase an annual minimum quantity of Zenivol, totalling over $4 million....Adjupharm says it will be filing for formal German government reimbursement for its sales of Zenivol....The distribution agreement follows a publication by the University of Western Australia research team’s results from its double-blind, placebo controlled trial of Zenivol in chronic insomnia patients in the peer-reviewed journal, SLEEP."

Clinical data • Licensing / partnership • CNS Disorders • Insomnia • Sleep Disorder

Zelira Therapeutics has clinical trial results of Zenivol published in SLEEP (Proactiveinvestors) - "Zelira Therapeutics...encouraged that the results of a trial in chronic insomnia patients of its proprietary cannabinoid ZLT101 formulation marketed as Zenivol® have been published in the peer-reviewed journal SLEEP®...The double-blind, placebo-controlled, cross-over trial was carried out by the University of Western Australia’s investigational team."

P1/2 data • CNS Disorders • Insomnia • Sleep Disorder

Treating Insomnia Symptoms with Medicinal Cannabis: A Randomized, Cross-Over Trial of the Efficacy of a Cannabinoid Medicine Compared with Placebo. (PubMed, Sleep) - "Two-weeks of nightly sublingual administration of a cannabinoid extract (ZTL-101) is well tolerated and improves insomnia symptoms and sleep quality in individuals with chronic insomnia symptoms."

Clinical • Journal • CNS Disorders • Insomnia • Sleep Disorder